Table 1.

Randomized subject baseline characteristics.

PopulationTreatment groupP value
Original studyDFMO (n = 144)Placebo (n = 147)
Age, y61.6 ± 10.760.2 ± 11.0
Gender
 Female57 (39.6%)59 (40.1%)
 Male87 (60.4%)88 (59.9%)
Race
 White144 (99.3%)147 (100%)
 Hispanic1 (0.7%)0 (0%)
Body surface area (m2)1.94 ± 0.231.99 ± 0.23
Prior NMSC4.2 ± 7.74.9 ± 5.70.10
Prior tumor rate2.3 ± 3.32.1 ± 3.40.08
Retrospective studyDFMO (n = 108)Placebo (n = 101)
Age, y61.4 ± 10.960.4 ± 11.0
Gender
 Female43 (39.8%)46 (45.5%)
 Male65 (60.2%)55 (54.5%)
Race
 White107 (99.5%)101 (100%)
 Hispanic1 (0.5%)0 (0%)
Body surface area (m2)1.94 ± 0.231.96 ± 0.23
Prior NMSC3.2 ± 3.05.5 ± 6.30.01
Prior tumor rate2.5 ± 3.52.4 ± 3.90.57

NOTE: For continuous data, mean ± SD is presented. For categorical data, N (%) are presented. Prior tumor rate is defined as the number of prior skin cancers divided by the time from initial diagnosis to randomization.